TITLE

CLINICAL OUTCOME OF PATIENTS WITH LOW GRADE DYSPLASIA IN BARRETT'S OESOPHAGUS

AUTHOR(S)
Gupta, S.; Amaout, A.; Theodossi, A.; Mendall, M. A.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA59
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Barrett's esophagus (BO) is a premalignant condition with histopathological evidence of dysplasia being the best marker of increased cancer risk. Of the 273 patients with histology confirmed BO, there were 45 patients with low grade dysplasia (LGD) and 2 patients with high grade dysplasia identified at some point. Authors undertook a retrospective analysis to determine the clinical outcome of patients with LGD. In the era of proton pump inhibitor therapy, about two third of cases of LGD in patients with underlying BO showed "regression" while none progressed to high grade dysplasia or carcinoma oesophagus.
ACCESSION #
13219042

 

Related Articles

  • Proton pump inhibitors reduce the incidence of dysplasia in Barrett's esophagus. Aguirre, Thomas; El-Serag, Hashem; Davis, Stephanie; Bhattacharyya, Achyut; Sampliner, Richard // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS23 

    An abstract of the article "Proton Pump Inhibitors Reduce the Incidence of Dysplasia in Barrett's Esophagus," by Thomas Aguirre, Hashem El-Serag, Stephanie Davis, Achyut Bhattacharyya and Richard Sampliner is presented.

  • Maintenance proton pump inhibitor (PPI) therapy decreases the incidence of esophageal cancer (CA) and high grade dysplasia (HGD) in Barrett's and chronic heartburn. Bank, Simmy; Singh, Ranvir; Indaram, Anant; Pooran, Nakechand // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS31 

    An abstract of the article "Maintenance Proton Pump Inhibitor (PPI) Therapy Decreases the Incidence of Esophageal Cancer (CA) and High Grade Dysplasia (HGD) in Barrett's and Chronic Heartburn," by Simmy Bank, Ranvir Singh, Anant Indaram and Nakechand Pooran is presented.

  • The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Su Jin Hong; Soo-Heon Park; Jeong Seop Moon; Woon Geon Shin; Jae Gyu Kim; Yong Chan Lee; Dong Ho Lee; Jae Young Jang; Kim, Jae J.; Hang-Lak Lee; Sang Woo Lee; Young Hwangbo; Jianming Xu; Bangmao Wang; Zhanxiong Xue; Fei Liu; Yaozong Yuan; Somchai Leelakusolvong; Dy, Frederick // Gut & Liver;Nov2016, Vol. 10 Issue 6, p910 

    Background/Aims: To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. Methods: A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg...

  • Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus. Wang, Judy S; Varro, Andrea; Lightdale, Charles J; Lertkowit, Nantaporn; Slack, Kristen N; Fingerhood, Michael L; Tsai, Wei Yann; Wang, Timothy C; Abrams, Julian A // American Journal of Gastroenterology;May2010, Vol. 105 Issue 5, p1039 

    OBJECTIVES:Proton pump inhibitors (PPIs) are frequently prescribed to patients with Barrett's esophagus (BE), but in a subset, they can induce significant hypergastrinemia. Elevated levels of gastrin have been associated with tumorigenic effects in a number of gastrointestinal cancers. We...

  • Barrett's oesophagus: size does matter. de Jonge, Pieter J. F.; Hvid-Jensen, Frederik // Gut;Feb2016, Vol. 65 Issue 2, p189 

    The article discusses research on the evidence for risk stratification of patients with Barrett's oesophagus (BO) according to BO length. It references a study by H. Pohl et al published within the issue. Topics covered include the estimated annual cancer transition rates in relation to...

  • DNA Content in Barrett's Esophagus and Esophageal Malignancy. McKinley, Matthew J.; Budman, Daniel R.; Grueneberg, Dorre; Bronzo, Richard L.; Weissman, Gary S.; Kahn, Ellen // American Journal of Gastroenterology;Oct1987, Vol. 82 Issue 10, p1012 

    Barrett's esophagus is a premalignant condition; endoscopic surveillance is often performed to search for early adenocarcinoma of the esophagus. In an attempt to detect early changes of malignancy, we have added the use of flow cytometry to routine endoscopic surveillance procedures. DNA...

  • Effect of zinc supplementation on N-nitrosomethylbenzylamine-induced forestomach tumor development and progression in tumor suppressor-deficient mouse strains. Sun, Jin; Liu, James; Pan, Xueliang; Quimby, Donald; Zanesi, Nicola; Druck, Teresa; Pfeifer, Gerd P.; Croce, Carlo M.; Fong, Louise Y.; Huebner, Kay // Carcinogenesis;Mar2011, Vol. 32 Issue 3, p351 

    Zinc deficiency is associated with high incidences of esophageal and other cancers in humans and leads to a highly proliferative hyperplastic condition in the upper gastrointestinal tract in laboratory rodents. Zn replenishment reduces the incidence of lingual, esophageal and forestomach tumors...

  • Cell culture models for studying the development of Barrett's esophagus: a systematic review. Bus, P.; Siersema, P.; Baal, J. // Cellular Oncology (2211-3428);Jun2012, Vol. 35 Issue 3, p149 

    Background: Barrett's esophagus (BE) is a premalignant condition caused by chronic gastroesophageal reflux. BE patients have an increased risk of developing esophageal adenocarcinoma (EAC). As many aspects of this condition are still unknown, there is a need for in vitro models to study BE...

  • Omeprazole was effective in the short term for uninvestigated dyspepsia. Rabeneck, L.; Souchek, J.; Wristers, k.; Talley, Nicholas J. // ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p70 

    Summarizes a study that determined whether a proton-pump inhibitor is effective in the treatment of patients with uninvestigated dyspepsia. Characterization of the patients; Main outcome measures; Results of the study.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics